Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.

NCCN updates pathology guidance in ovarian cancer

By staff writers

December 2, 2019 -- The National Comprehensive Cancer Network (NCCN) included an update to a section on principles in pathology in its latest practice guidelines on ovarian cancer, including fallopian tube cancer.

In the new version, released on November 26, the guidelines now read:

It is difficult to distinguish based on histology between primary mucinous ovarian carcinomas and gastrointestinal metastases. PAX8 immunostaining is typical of primary ovarian tumors, although the absence of PAX8 does not rule out ovary as the primary site, while SATB2 is consistent with colonic origin. Metastastic colorectal adenocarcinomas also usually are positive for CK20 and CEA.

Other changes in the revised guidelines pertain to treatment with pharmaceuticals, including bevacizumab (Avastin, Roche) and the targeted poly (ADP-ribose) polymerase (PARP) inhibitor niraparib (Zejula, GlaxoSmithKline).

CA-125 blood test better than expected in ovarian cancer
The performance of the cancer antigen 125 (CA-125) blood test for detecting ovarian cancer surpassed expectations in a study of more than 50,000 symptomatic...
CMS plans broader coverage for NGS in breast, ovarian cancer
The U.S. Centers for Medicare and Medicaid Services (CMS) has proposed broad national coverage for next-generation sequencing (NGS) in Medicare patients...
Myriad's myChoice PARP companion test clears FDA
Myriad Genetics' myChoice CDx has received U.S. Food and Drug Administration (FDA) premarket approval as a companion diagnostic to guide the use of GlaxoSmithKline's...
Ovarian cancer blood test could reduce unnecessary surgeries
A blood test for 11 plasma proteins may help judge whether women have ovarian cancer, even in its early stages, potentially helping to avoid surgeries,...

Copyright © 2019

Last Updated np 12/2/2019 2:05:06 PM